Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Alabama at Birmingham

Sites in Birmingham, AL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1234
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Alabama at Birmingham, Birmingham, AL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Alabama at Birmingham, Birmingham, AL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 349–360 of 1,234 matching trials with a site at University of Alabama at Birmingham, Birmingham, AL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1 Interventional

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

NCT07222267
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer, Advanced Solid Tumor
Interventions
BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist, Aromatase Inhibitor
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
6
States / cities
Birmingham, Alabama • New Haven, Connecticut • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

NCT04973605
Status at this site: Recruiting
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Sonrotoclax, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • Irvine, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Active, not recruiting Phase 3 Interventional

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

NCT06260722
Site status not listed — check the official record
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Retatrutide, Semaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
38
States / cities
Birmingham, Alabama • Escondido, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Recruiting Phase 1 Interventional

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07219212
Status at this site: Recruiting
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
JNJ-90301900, Cisplatin, Intensity Modulated Radiation Therapy (IMRT), Carboplatin, Paclitaxel
Drug · Radiation
Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

NCT07036523
Site status not listed — check the official record
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BI 765423, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Gainesville, Florida • Ocala, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Recruiting Not applicable Interventional

A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial

NCT05805709
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Study Physician/Advance Practice Provider, Nurse Navigator, Pharmacist, Patient Education
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Birmingham, Alabama • New Haven, Connecticut • Weston, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

NCT07227454
Status at this site: Recruiting
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Midazolam, Oral Placebo, Intranasal Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

NCT05347095
Site status not listed — check the official record
View directory record Official record
Conditions
Fistulizing Crohns Disease, Perianal Crohns Disease
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen-Cilag Ltd.
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Recruiting Phase 3 Interventional

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

NCT06533098
Status at this site: Recruiting
View directory record Official record
Conditions
Thrombocytopenia, Neonatal Alloimmune
Interventions
Nipocalimab, Intravenous immunoglobulins (IVIG), Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
13
States / cities
Birmingham, Alabama • Sacramento, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

NCT05488314
Site status not listed — check the official record
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Capmatinib, Amivantamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Birmingham, Alabama • Cerritos, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

NCT07160244
Status at this site: Recruiting
View directory record Official record
Conditions
Healthy
Interventions
Multivalent Group B streptococcus vaccine, Placebo, Infanrix hexa, Prevenar 20, Pediarix, Prevnar 20, Infanrix
Biological
Lead sponsor
Pfizer
Industry
Eligibility
1 Day to 49 Years
Enrollment
6,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
120
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Recruiting Phase 2 Interventional

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04634552
Status at this site: Recruiting
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Talquetamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 1:44 PM EDT

About this University of Alabama at Birmingham institution page

What this page lists
ClinicalTrials.gov records that list University of Alabama at Birmingham in Birmingham, AL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.